Mestinon Indication:

For the treatment of myasthenia gravis.

Mestinon Mechanism Of Action:

Mestinon inhibits acetylcholinesterase in the synaptic cleft by competing with acetylcholine for attachment to acetylcholinesterase, thus slowing down the hydrolysis of acetylcholine, and thereby increases efficiency of cholinergic transmission in the neuromuscular junction and prolonges the effects of acetylcholine.

Mestinon Drug Interactions:

Betamethasone The corticosteroid decreases the effect of anticholinesterases
Corticotropin The corticosteroid decreases the effect of anticholinesterases
Cortisone acetate The corticosteroid decreases the effect of anticholinesterases
Cosyntropin The corticosteroid decreases the effect of anticholinesterases
Dexamethasone The corticosteroid decreases the effect of anticholinesterases
Fludrocortisone The corticosteroid decreases the effect of anticholinesterases
Hydrocortisone The corticosteroid decreases the effect of anticholinesterases
Methylprednisolone The corticosteroid decreases the effect of anticholinesterases
Paramethasone The corticosteroid decreases the effect of anticholinesterases
Prednisolone The corticosteroid decreases the effect of anticholinesterases
Prednisone The corticosteroid decreases the effect of anticholinesterases
Succinylcholine The corticosteroid decreases the effect of anticholinesterases
Triamcinolone The corticosteroid decreases the effect of anticholinesterases

Mestinon Food Interactions:

Not Available

Mestinon Generic Name:

Synonyms:

  • Pyridostigmine Bromide
  • Pyridostigmine Bromine
  • Pyridostigminum
  • Pyridine N-Oxide

Drug Type:

Small Molecule; Approved

Absorption:

Poorly absorbed from the GI tract with an oral bioavailability of 7.6 +/- 2.4%.

Toxicity (Overdose):

Not Available

Protein Binding:

Not Available

Biotransformation:

Hydrolysis by cholinesterases and by liver.

Half Life:

3 hours following oral administration.

Dosage Forms of Mestinon:

Tablet Oral
Tablet, extended release Oral

Chemical IUPAC Name:

(1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate

Organisms Affected:

Humans and other mammals

Mestinon to general, pharmacology

General, pharmacology..